泰和科技(300801.SZ):暫未與清華大學合作開發“基於腦機接口技術的多模態人機交互系統”
格隆匯7月7日丨泰和科技(300801.SZ)在互動平臺表示,目前泰和科技暫未與清華大學合作開發“基於腦機接口技術的多模態人機交互系統”。在人機交互領域,泰和科技設立了儀器設備項目組,自主研發了腦波生物反饋裝置,可以用於腦電生物反饋訓練與治療,有兩款產品,個人款可以作爲冥想輔助,通過阿爾法波或西塔波反饋,可以快速進入阿爾法波或西塔波狀態,另一款可以作爲集體訓練和輔助治療用,目前設計已經完成,進入了樣機測試階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.